Zacks Rating on Accuray Incorporated (ARAY)

Accuray Incorporated (ARAY) : 3 brokerage houses believe that Accuray Incorporated (ARAY) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Accuray Incorporated (ARAY). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.5.

Accuray Incorporated (ARAY) : The most positive equity analysts on Accuray Incorporated (ARAY) expects the shares to touch $12, whereas, the least positive believes that the stock will trade at $8 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $9.75 with an expected fluctuation of $2.06 from the mean.


Accuray Incorporated has lost 2.55% in the last five trading days and dropped 0.93% in the last 4 weeks. Accuray Incorporated has dropped 2.55% during the last 3-month period . Year-to-Date the stock performance stands at -20.89%. Accuray Incorporated (NASDAQ:ARAY): stock turned positive on Tuesday. Though the stock opened at $5.33, the bulls momentum made the stock top out at $5.41 level for the day. The stock recorded a low of $5.32 and closed the trading day at $5.34, in the green by 0.56%. The total traded volume for the day was 466,465. The stock had closed at $5.31 in the previous days trading.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.